US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

0.7171

+0.00500.70%

Post-market: 0.72530.0082+1.14%16:00 EDT

Volume:31.07K

Turnover:22.13K

Market Cap:5.34M

PE:-0.14

High:0.7250

Open:0.6980

Low:0.6900

Close:0.7121

52wk High:7.50

52wk Low:0.6500

Shares:7.44M

Float Shares:7.33M

Volume Ratio:0.56

T/O Rate:0.42%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.2928

EPS(LYR):-12.6857

ROE:-85.84%

ROA:-49.52%

PB:0.35

PE(LYR):-0.06

Loading ...

Overview Company News Filings

BRIEF-Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort From Its Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients

THOMSON REUTERS

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Sets Deadline for Shareholder Proposals

Pasithea Therapeutics Receives Nasdaq Notice for Non-Compliance with $1 Minimum Bid Price Rule

Pasithea Therapeutics Increases Offering Price to $4.23M, Registers Additional $2.15M in Common Stock Sales

Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study

Tiago Marques, CEO of Pasithea Therapeutics, Reports Disposal of Common Shares

BRIEF-Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site

Press Release: Pasithea Therapeutics Announces Closing of $5 Million Public Offering

BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering

Pasithea Therapeutics Prices $5 Million Public Offering

MT Newswires Live

Pasithea Therapeutics 3.57M share Secondary priced at $1.40

Pasithea Therapeutics Corporation Unveils Presentation on Development and Commercialization Plans for PAS-004 in Advanced Cancer Treatment

BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing

Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KTTA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KTTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.7171,"timestamp":1755892800000,"preClose":0.7121,"halted":0,"volume":31069,"hourTrading":{"tag":"盘后","latestPrice":0.7253,"preClose":0.7171,"latestTime":"16:00 EDT","volume":30,"amount":21.758999999999997,"timestamp":1755892801244},"delay":0,"floatShares":7331217,"shares":7443577,"eps":-5.292805,"marketStatus":"Post-Mkt","change":0.005,"latestTime":"08-22 16:43:40 EDT","open":0.698,"high":0.725,"low":0.69,"amount":22134.489094,"amplitude":0.04915,"askPrice":0.7873,"askSize":100,"bidPrice":0.69,"bidSize":271,"shortable":3,"etf":0,"ttmEps":-5.292805,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755907200000},"marketStatusCode":4,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.7121,"preHourTrading":{"tag":"盘前","latestPrice":0.695,"preClose":0.7121,"latestTime":"09:29 EDT","volume":363,"amount":251.55829215,"timestamp":1755869399417},"postHourTrading":{"tag":"盘后","latestPrice":0.7253,"preClose":0.7171,"latestTime":"16:00 EDT","volume":30,"amount":21.758999999999997,"timestamp":1755892801244},"volumeRatio":0.556844},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KTTA\",,,,,undefined,":{"symbol":"KTTA","floatShares":7331217,"roa":"-49.52%","roe":"-85.84%","lyrEps":-12.685715,"volumeRatio":0.556844,"shares":7443577,"dividePrice":0,"high":0.725,"amplitude":0.04915,"preClose":0.7121,"low":0.69,"week52Low":0.65,"pbRate":"0.35","psRate":"10.97","week52High":7.5,"institutionHeld":0,"latestPrice":0.7171,"committee":0.460916,"eps":-5.292805,"divideRate":0,"volume":31069,"delay":0,"ttmEps":-5.292805,"open":0.698,"prevYearClose":3.15,"prevWeekClose":0.7027,"prevMonthClose":0.7251,"prevQuarterClose":0.7213,"fiveDayClose":0.7027,"twentyDayClose":0.726,"sixtyDayClose":0.8956},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KTTA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"KTTA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"","actualEps":-0.66},{"market":"US","date":"2025-03-24","symbol":"KTTA","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-2.41},{"market":"US","date":"2024-08-13","symbol":"KTTA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-3.71},{"market":"US","date":"2024-05-14","symbol":"KTTA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.7},{"market":"US","date":"2024-03-28","symbol":"KTTA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KTTA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KTTA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KTTA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KTTA","date":"2025-08-21","current":-0.390076,"percent":0.743215,"low":-1093.683193,"twenty":-8.116369,"median":-0.657281,"eighty":-0.335654,"high":-0.082689,"avg":-37.044592,"sd":145.473193,"marketCap":5249210},"quantilePoints":[{"date":"2021-08-13","current":-1093.683193,"twenty":-1093.683193,"median":-1093.683193,"eighty":-1093.683193,"marketCap":67235268},{"date":"2021-09-17","current":-669.104496,"twenty":-1093.683193,"median":-756.194287,"eighty":-671.674393,"marketCap":41133868},{"date":"2021-09-24","current":-626.621673,"twenty":-1093.683193,"median":-671.674393,"eighty":-632.994101,"marketCap":38522194},{"date":"2021-10-01","current":-609.628538,"twenty":-891.189849,"median":-656.359653,"eighty":-608.804372,"marketCap":37477524},{"date":"2021-10-08","current":-556.525018,"twenty":-729.430106,"median":-641.490663,"eighty":-578.616078,"marketCap":34212932},{"date":"2021-10-15","current":-632.994095,"twenty":-687.639563,"median":-626.621673,"eighty":-571.393991,"marketCap":38913945},{"date":"2021-10-22","current":-571.393991,"twenty":-671.674393,"median":-609.628538,"eighty":-571.393991,"marketCap":35127017},{"date":"2021-10-29","current":-601.13197,"twenty":-670.132455,"median":-607.568124,"eighty":-571.393991,"marketCap":36955189},{"date":"2021-11-05","current":-537.407736,"twenty":-661.45759,"median":-596.894317,"eighty":-566.296057,"marketCap":33037678},{"date":"2021-11-12","current":-548.02845,"twenty":-653.810678,"median":-586.262981,"eighty":-556.525018,"marketCap":33690597},{"date":"2021-11-19","current":-10.979296,"twenty":-648.287908,"median":-575.642283,"eighty":-545.904304,"marketCap":31303839},{"date":"2021-11-26","current":-18.576783,"twenty":-642.340318,"median":-572.456064,"eighty":-536.133248,"marketCap":52965567},{"date":"2021-12-03","current":-21.49554,"twenty":-635.54307,"median":-571.393991,"eighty":-511.493207,"marketCap":61287438},{"date":"2021-12-10","current":-17.503511,"twenty":-631.294785,"median":-567.145715,"eighty":-26.651141,"marketCap":49905485},{"date":"2021-12-17","current":-11.361928,"twenty":-627.896161,"median":-558.649148,"eighty":-21.219169,"marketCap":32394789},{"date":"2021-12-23","current":-15.430727,"twenty":-624.92236,"median":-556.525018,"eighty":-19.683773,"marketCap":43995625},{"date":"2021-12-31","current":-13.588252,"twenty":-616.425792,"median":-549.090515,"eighty":-17.135016,"marketCap":38742416},{"date":"2022-01-07","current":-11.438698,"twenty":-609.628538,"median":-545.904304,"eighty":-14.877985,"marketCap":32613672},{"date":"2022-01-14","current":-10.59423,"twenty":-609.216455,"median":-536.345663,"eighty":-14.064224,"marketCap":30205951},{"date":"2022-01-21","current":-9.596223,"twenty":-607.568124,"median":-527.849104,"eighty":-13.434712,"marketCap":27360463},{"date":"2022-01-28","current":-8.598216,"twenty":-601.13197,"median":-505.545611,"eighty":-11.515468,"marketCap":24514975},{"date":"2022-02-04","current":-9.135604,"twenty":-599.00784,"median":-30.170526,"eighty":-11.361928,"marketCap":26047161},{"date":"2022-02-11","current":-9.442684,"twenty":-594.780793,"median":-25.717878,"eighty":-10.979296,"marketCap":26922696},{"date":"2022-02-18","current":-8.367907,"twenty":-594.759548,"median":-21.265231,"eighty":-10.238077,"marketCap":23858324},{"date":"2022-02-25","current":-7.830518,"twenty":-587.962294,"median":-19.883375,"eighty":-9.964718,"marketCap":22326138},{"date":"2022-03-04","current":-8.674986,"twenty":-582.86436,"median":-18.576783,"eighty":-9.442684,"marketCap":24733859},{"date":"2022-03-11","current":-9.212374,"twenty":-576.916767,"median":-17.273201,"eighty":-9.35056,"marketCap":26266045},{"date":"2022-03-18","current":-10.210381,"twenty":-575.642283,"median":-15.430727,"eighty":-9.35056,"marketCap":29111533},{"date":"2022-03-25","current":-10.287151,"twenty":-573.942966,"median":-14.739799,"eighty":-9.365914,"marketCap":29330417},{"date":"2022-04-01","current":-13.65563,"twenty":-571.81882,"median":-14.35595,"eighty":-9.42733,"marketCap":29680798},{"date":"2022-04-08","current":-13.126342,"twenty":-571.393991,"median":-13.905179,"eighty":-9.442684,"marketCap":28530380},{"date":"2022-04-14","current":-14.290775,"twenty":-571.393991,"median":-13.751639,"eighty":-9.488745,"marketCap":31061300},{"date":"2022-04-22","current":-12.279481,"twenty":-570.119513,"median":-13.588252,"eighty":-9.565515,"marketCap":26689710},{"date":"2022-04-29","current":-12.702912,"twenty":-567.995373,"median":-13.285128,"eighty":-9.596223,"marketCap":27610045},{"date":"2022-05-06","current":-10.967906,"twenty":-567.145715,"median":-13.126342,"eighty":-9.596223,"marketCap":23838973},{"date":"2022-05-13","current":-9.630924,"twenty":-565.871227,"median":-13.073413,"eighty":-9.617044,"marketCap":20933015},{"date":"2022-05-20","current":-6.517075,"twenty":-561.198116,"median":-13.020484,"eighty":-9.488745,"marketCap":20842597},{"date":"2022-05-27","current":-6.082361,"twenty":-557.37467,"median":-12.649983,"eighty":-9.335206,"marketCap":19452314},{"date":"2022-06-03","current":-7.244512,"twenty":-556.525018,"median":-12.385339,"eighty":-9.289144,"marketCap":23169050},{"date":"2022-06-10","current":-7.427281,"twenty":-556.525018,"median":-12.385339,"eighty":-9.135604,"marketCap":23753574},{"date":"2022-06-17","current":-7.427281,"twenty":-553.976043,"median":-12.279481,"eighty":-8.936003,"marketCap":23753574},{"date":"2022-06-24","current":-7.093053,"twenty":-549.727754,"median":-12.279481,"eighty":-8.69034,"marketCap":22684663},{"date":"2022-07-01","current":-7.281648,"twenty":-547.603621,"median":-11.976086,"eighty":-8.306491,"marketCap":23287818},{"date":"2022-07-08","current":-7.791364,"twenty":-545.904304,"median":-11.515468,"eighty":-8.191854,"marketCap":24917965},{"date":"2022-07-15","current":-9.147016,"twenty":-545.904304,"median":-11.435659,"eighty":-8.082629,"marketCap":29253549},{"date":"2022-07-22","current":-9.432861,"twenty":-543.780158,"median":-11.361928,"eighty":-8.166979,"marketCap":30167723},{"date":"2022-07-29","current":-9.473696,"twenty":-537.407736,"median":-11.086562,"eighty":-8.191854,"marketCap":30298319},{"date":"2022-08-05","current":-10.127054,"twenty":-535.28359,"median":-10.967906,"eighty":-8.214367,"marketCap":32387858},{"date":"2022-08-12","current":-10.780413,"twenty":-533.159461,"median":-10.725706,"eighty":-8.291137,"marketCap":34477398},{"date":"2022-08-19","current":-6.949802,"twenty":-522.538747,"median":-10.59423,"eighty":-8.082629,"marketCap":35642748},{"date":"2022-08-26","current":-6.194955,"twenty":-520.414601,"median":-10.479076,"eighty":-7.830518,"marketCap":31771438},{"date":"2022-09-02","current":-5.986721,"twenty":-505.545611,"median":-10.363921,"eighty":-7.791364,"marketCap":30703491},{"date":"2022-09-09","current":-6.455247,"twenty":-497.049053,"median":-10.238077,"eighty":-7.500098,"marketCap":33106373},{"date":"2022-09-16","current":-6.559364,"twenty":-125.08671,"median":-10.210381,"eighty":-7.427135,"marketCap":33640346},{"date":"2022-09-23","current":-6.194955,"twenty":-28.696546,"median":-10.208724,"eighty":-7.354465,"marketCap":31771438},{"date":"2022-09-30","current":-6.559364,"twenty":-26.296891,"median":-10.091948,"eighty":-7.310774,"marketCap":33640346},{"date":"2022-10-07","current":-6.403188,"twenty":-25.76283,"median":-9.980072,"eighty":-7.237376,"marketCap":32839386},{"date":"2022-10-14","current":-6.507305,"twenty":-25.410799,"median":-9.903302,"eighty":-7.06116,"marketCap":33373360},{"date":"2022-10-21","current":-5.518195,"twenty":-22.263238,"median":-9.630924,"eighty":-6.814917,"marketCap":28300609},{"date":"2022-10-28","current":-5.622312,"twenty":-21.127045,"median":-9.596223,"eighty":-6.757186,"marketCap":28834583},{"date":"2022-11-04","current":-6.159301,"twenty":-20.175099,"median":-9.555365,"eighty":-6.611422,"marketCap":31588583},{"date":"2022-11-11","current":-5.988209,"twenty":-19.837313,"median":-9.494114,"eighty":-6.559364,"marketCap":30711122},{"date":"2022-11-18","current":-3.744034,"twenty":-19.683773,"median":-9.442684,"eighty":-6.515619,"marketCap":30658474},{"date":"2022-11-25","current":-3.607588,"twenty":-19.007296,"median":-9.432861,"eighty":-6.507305,"marketCap":29541174},{"date":"2022-12-02","current":-3.679026,"twenty":-18.521192,"median":-9.392026,"eighty":-6.455247,"marketCap":30126148},{"date":"2022-12-09","current":-3.500432,"twenty":-17.895759,"median":-9.365914,"eighty":-6.382365,"marketCap":28663714},{"date":"2022-12-16","current":-2.714621,"twenty":-17.22714,"median":-9.310356,"eighty":-6.278248,"marketCap":22229002},{"date":"2022-12-23","current":-2.062755,"twenty":-16.305902,"median":-9.289144,"eighty":-6.245813,"marketCap":16891117},{"date":"2022-12-30","current":-2.292069,"twenty":-15.661036,"median":-9.289144,"eighty":-6.194955,"marketCap":18768883},{"date":"2023-01-06","current":-2.309214,"twenty":-15.369311,"median":-9.229503,"eighty":-6.161226,"marketCap":18909276},{"date":"2023-01-13","current":-2.488168,"twenty":-15.06293,"median":-9.179695,"eighty":-6.142896,"marketCap":20374665},{"date":"2023-01-20","current":-2.447802,"twenty":-14.820063,"median":-9.135604,"eighty":-6.090838,"marketCap":20044125},{"date":"2023-01-27","current":-2.489236,"twenty":-14.816569,"median":-8.982065,"eighty":-6.045239,"marketCap":20383410},{"date":"2023-02-03","current":-2.421728,"twenty":-14.663029,"median":-8.86691,"eighty":-5.986721,"marketCap":19830610},{"date":"2023-02-10","current":-2.088826,"twenty":-14.35595,"median":-8.697833,"eighty":-5.934662,"marketCap":17104603},{"date":"2023-02-17","current":-2.096687,"twenty":-14.290775,"median":-8.636601,"eighty":-5.726429,"marketCap":17168979},{"date":"2023-02-24","current":-1.752716,"twenty":-14.158667,"median":-8.534493,"eighty":-5.622312,"marketCap":14352331},{"date":"2023-03-03","current":-1.780577,"twenty":-14.064224,"median":-8.291137,"eighty":-5.171792,"marketCap":14580470},{"date":"2023-03-10","current":-1.729249,"twenty":-13.818964,"median":-8.20311,"eighty":-3.679026,"marketCap":14160167},{"date":"2023-03-17","current":-1.535904,"twenty":-13.745731,"median":-8.082629,"eighty":-3.607588,"marketCap":12576935},{"date":"2023-03-24","current":-1.428748,"twenty":-13.672862,"median":-7.885734,"eighty":-3.570084,"marketCap":11699475},{"date":"2023-03-31","current":-1.339451,"twenty":-13.601728,"median":-7.830518,"eighty":-3.500432,"marketCap":10968258},{"date":"2023-04-05","current":-1.428391,"twenty":-13.526836,"median":-7.810941,"eighty":-3.465357,"marketCap":11696550},{"date":"2023-04-14","current":-0.749882,"twenty":-13.39605,"median":-7.718547,"eighty":-2.874212,"marketCap":10450696},{"date":"2023-04-21","current":-0.836681,"twenty":-13.316885,"median":-7.500098,"eighty":-2.62461,"marketCap":11660364},{"date":"2023-04-28","current":-0.656147,"twenty":-13.211028,"median":-7.436975,"eighty":-2.543242,"marketCap":9144359},{"date":"2023-05-05","current":-0.581159,"twenty":-13.126342,"median":-7.426917,"eighty":-2.49638,"marketCap":8099289},{"date":"2023-05-12","current":-0.674894,"twenty":-13.126342,"median":-7.354465,"eighty":-2.482807,"marketCap":9405626},{"date":"2023-05-18","current":-0.558853,"twenty":-13.126342,"median":-7.354465,"eighty":-2.427442,"marketCap":8885704},{"date":"2023-05-26","current":-0.600098,"twenty":-13.126342,"median":-7.33626,"eighty":-2.358077,"marketCap":9541485},{"date":"2023-06-02","current":-0.575285,"twenty":-13.062827,"median":-7.281648,"eighty":-2.303499,"marketCap":9146971},{"date":"2023-06-09","current":-0.79531,"twenty":-13.020484,"median":-7.244512,"eighty":-2.280424,"marketCap":12645342},{"date":"2023-06-16","current":-0.761131,"twenty":-13.020484,"median":-7.134559,"eighty":-2.147122,"marketCap":12101905},{"date":"2023-06-23","current":-0.709863,"twenty":-12.978141,"median":-7.063199,"eighty":-2.090973,"marketCap":11286751},{"date":"2023-06-30","current":-0.788737,"twenty":-12.808769,"median":-6.990382,"eighty":-2.071684,"marketCap":12540835},{"date":"2023-07-07","current":-0.838033,"twenty":-12.724083,"median":-6.819656,"eighty":-2.046396,"marketCap":13324637},{"date":"2023-07-14","current":-0.755052,"twenty":-12.639397,"median":-6.767598,"eighty":-1.946312,"marketCap":12005237},{"date":"2023-07-21","current":-0.974419,"twenty":-12.512368,"median":-6.767598,"eighty":-1.782717,"marketCap":15493156},{"date":"2023-07-28","current":-0.971133,"twenty":-12.385339,"median":-6.650466,"eighty":-1.757289,"marketCap":15440903},{"date":"2023-08-04","current":-0.973269,"twenty":-12.385339,"median":-6.611422,"eighty":-1.737636,"marketCap":15474868},{"date":"2023-08-11","current":-1.029301,"twenty":-12.385339,"median":-6.559364,"eighty":-1.647346,"marketCap":16365772},{"date":"2023-08-18","current":-0.922144,"twenty":-12.385339,"median":-6.559364,"eighty":-1.54019,"marketCap":15680815},{"date":"2023-08-25","current":-0.936135,"twenty":-12.342996,"median":-6.513434,"eighty":-1.443036,"marketCap":15918720},{"date":"2023-09-01","current":-0.930908,"twenty":-12.279481,"median":-6.507305,"eighty":-1.400387,"marketCap":15829832},{"date":"2023-09-07","current":-0.9532,"twenty":-12.279481,"median":-6.507305,"eighty":-1.339451,"marketCap":16208912},{"date":"2023-09-15","current":-0.799458,"twenty":-12.279481,"median":-6.507305,"eighty":-1.028381,"marketCap":13594571},{"date":"2023-09-22","current":-0.544841,"twenty":-12.279481,"median":-6.455247,"eighty":-0.986118,"marketCap":9264880},{"date":"2023-09-29","current":-0.551575,"twenty":-12.189568,"median":-6.403188,"eighty":-0.977377,"marketCap":9379390},{"date":"2023-10-06","current":-0.518763,"twenty":-12.037502,"median":-6.320693,"eighty":-0.970344,"marketCap":8821415},{"date":"2023-10-13","current":-0.530699,"twenty":-11.976086,"median":-6.247013,"eighty":-0.956072,"marketCap":9024389},{"date":"2023-10-20","current":-0.575911,"twenty":-11.699715,"median":-6.247013,"eighty":-0.93715,"marketCap":9793212},{"date":"2023-10-23","current":-0.575911,"twenty":-11.607592,"median":-6.247013,"eighty":-0.935766,"marketCap":9793212},{"date":"2023-11-03","current":-0.39211,"twenty":-11.454052,"median":-6.205643,"eighty":-0.929985,"marketCap":6667719},{"date":"2023-11-10","current":-0.459259,"twenty":-11.438698,"median":-6.194955,"eighty":-0.92073,"marketCap":7809566},{"date":"2023-11-17","current":-0.390317,"twenty":-11.433836,"median":-6.159301,"eighty":-0.839196,"marketCap":6257237},{"date":"2023-11-24","current":-0.402144,"twenty":-11.390205,"median":-6.151098,"eighty":-0.827299,"marketCap":6446851},{"date":"2023-12-01","current":-0.42372,"twenty":-11.361928,"median":-6.10227,"eighty":-0.805526,"marketCap":6792739},{"date":"2023-12-08","current":-0.428009,"twenty":-11.315866,"median":-6.090838,"eighty":-0.797799,"marketCap":6861499},{"date":"2023-12-15","current":-0.482209,"twenty":-11.185028,"median":-6.067797,"eighty":-0.787784,"marketCap":7730387},{"date":"2023-12-22","current":-0.37173,"twenty":-11.080219,"median":-6.002517,"eighty":-0.7805,"marketCap":5959274},{"date":"2023-12-29","current":-0.506905,"twenty":-11.039738,"median":-5.988209,"eighty":-0.774737,"marketCap":8126282},{"date":"2024-01-05","current":-0.490144,"twenty":-10.994407,"median":-5.986721,"eighty":-0.773619,"marketCap":7857593},{"date":"2024-01-12","current":-0.487408,"twenty":-10.970184,"median":-5.986721,"eighty":-0.764089,"marketCap":7813732},{"date":"2024-01-19","current":-0.454914,"twenty":-10.929162,"median":-5.874148,"eighty":-0.758896,"marketCap":7292817},{"date":"2024-01-26","current":-0.452965,"twenty":-10.829581,"median":-5.726429,"eighty":-0.751007,"marketCap":7261562},{"date":"2024-02-02","current":-0.428919,"twenty":-10.714765,"median":-5.67437,"eighty":-0.72911,"marketCap":6876084},{"date":"2024-02-09","current":-0.378229,"twenty":-10.624938,"median":-5.600708,"eighty":-0.690979,"marketCap":6063456},{"date":"2024-02-16","current":-0.470303,"twenty":-10.59423,"median":-5.518195,"eighty":-0.661662,"marketCap":7539522},{"date":"2024-02-23","current":-0.467912,"twenty":-10.588724,"median":-3.750463,"eighty":-0.651122,"marketCap":7501183},{"date":"2024-03-01","current":-0.519902,"twenty":-10.555264,"median":-3.679026,"eighty":-0.62303,"marketCap":8334648},{"date":"2024-03-08","current":-0.467918,"twenty":-10.486753,"median":-3.607588,"eighty":-0.60253,"marketCap":7501287},{"date":"2024-03-15","current":-0.467912,"twenty":-10.440691,"median":-3.607588,"eighty":-0.583874,"marketCap":7501183},{"date":"2024-03-22","current":-0.466066,"twenty":-10.409983,"median":-3.57187,"eighty":-0.577049,"marketCap":7471595},{"date":"2024-03-28","current":-0.464662,"twenty":-10.348567,"median":-3.536865,"eighty":-0.575543,"marketCap":7449091},{"date":"2024-04-05","current":-0.57144,"twenty":-10.277336,"median":-3.500432,"eighty":-0.575034,"marketCap":9121131},{"date":"2024-04-12","current":-0.499602,"twenty":-10.232538,"median":-3.465071,"eighty":-0.559641,"marketCap":7974474},{"date":"2024-04-19","current":-0.466948,"twenty":-10.210381,"median":-2.953758,"eighty":-0.555795,"marketCap":7453267},{"date":"2024-04-26","current":-0.472826,"twenty":-10.210381,"median":-2.714621,"eighty":-0.546188,"marketCap":7547084},{"date":"2024-05-03","current":-0.451927,"twenty":-10.210381,"median":-2.602107,"eighty":-0.539063,"marketCap":7213511},{"date":"2024-05-10","current":-0.501555,"twenty":-10.21005,"median":-2.572103,"eighty":-0.531663,"marketCap":8005642},{"date":"2024-05-17","current":-0.416074,"twenty":-10.193701,"median":-2.505399,"eighty":-0.520528,"marketCap":6775697},{"date":"2024-05-24","current":-0.419288,"twenty":-10.1323,"median":-2.491379,"eighty":-0.517907,"marketCap":6828026},{"date":"2024-05-31","current":-0.374766,"twenty":-10.127054,"median":-2.488168,"eighty":-0.505605,"marketCap":6103000},{"date":"2024-06-07","current":-0.36451,"twenty":-10.056842,"median":-2.456196,"eighty":-0.501555,"marketCap":5935976},{"date":"2024-06-14","current":-0.365112,"twenty":-10.047676,"median":-2.425835,"eighty":-0.493908,"marketCap":5945783},{"date":"2024-06-21","current":-0.314054,"twenty":-10.006197,"median":-2.408333,"eighty":-0.492726,"marketCap":5114314},{"date":"2024-06-28","current":-0.336969,"twenty":-9.980072,"median":-2.377973,"eighty":-0.490144,"marketCap":5487484},{"date":"2024-07-05","current":-0.331844,"twenty":-9.956506,"median":-2.333681,"eighty":-0.487408,"marketCap":5404024},{"date":"2024-07-12","current":-0.336329,"twenty":-9.912764,"median":-2.294926,"eighty":-0.482209,"marketCap":5477052},{"date":"2024-07-15","current":-0.358751,"twenty":-9.903302,"median":-2.293497,"eighty":-0.482209,"marketCap":5842188},{"date":"2024-08-02","current":-0.320954,"twenty":-9.903302,"median":-2.292069,"eighty":-0.481169,"marketCap":5226672},{"date":"2024-08-09","current":-0.310704,"twenty":-9.891593,"median":-2.279389,"eighty":-0.474405,"marketCap":5059752},{"date":"2024-08-16","current":-0.292199,"twenty":-9.80199,"median":-2.153123,"eighty":-0.473282,"marketCap":4788508},{"date":"2024-08-23","current":-0.299561,"twenty":-9.623984,"median":-2.117225,"eighty":-0.472794,"marketCap":4909164},{"date":"2024-08-30","current":-0.300103,"twenty":-9.596223,"median":-2.088826,"eighty":-0.470393,"marketCap":4918039},{"date":"2024-09-06","current":-0.272682,"twenty":-9.596223,"median":-2.071684,"eighty":-0.467918,"marketCap":4468666},{"date":"2024-09-13","current":-0.251339,"twenty":-9.596223,"median":-2.055611,"eighty":-0.466948,"marketCap":4118899},{"date":"2024-09-20","current":-0.305811,"twenty":-9.556182,"median":-2.005265,"eighty":-0.464662,"marketCap":5011588},{"date":"2024-09-27","current":-0.372708,"twenty":-9.555365,"median":-1.857015,"eighty":-0.464013,"marketCap":6107873},{"date":"2024-10-04","current":-0.333462,"twenty":-9.519453,"median":-1.780577,"eighty":-0.462388,"marketCap":5464719},{"date":"2024-10-11","current":-0.307723,"twenty":-9.514531,"median":-1.762986,"eighty":-0.459259,"marketCap":5042911},{"date":"2024-10-18","current":-0.254206,"twenty":-9.473696,"median":-1.752716,"eighty":-0.454914,"marketCap":4165883},{"date":"2024-10-25","current":-0.257597,"twenty":-9.473696,"median":-1.739733,"eighty":-0.453887,"marketCap":4221452},{"date":"2024-10-31","current":-0.251858,"twenty":-9.448886,"median":-1.696995,"eighty":-0.452009,"marketCap":4127410},{"date":"2024-11-08","current":-0.232092,"twenty":-9.442684,"median":-1.64306,"eighty":-0.451927,"marketCap":3803486},{"date":"2024-11-15","current":-0.264925,"twenty":-9.434826,"median":-1.559122,"eighty":-0.448416,"marketCap":4179209},{"date":"2024-11-22","current":-0.255291,"twenty":-9.400193,"median":-1.53519,"eighty":-0.441407,"marketCap":4027237},{"date":"2024-11-29","current":-0.248066,"twenty":-9.392026,"median":-1.464467,"eighty":-0.436176,"marketCap":3913259},{"date":"2024-12-06","current":-0.22639,"twenty":-9.392026,"median":-1.42857,"eighty":-0.428919,"marketCap":3571324},{"date":"2024-12-13","current":-0.214348,"twenty":-9.376359,"median":-1.339451,"eighty":-0.427079,"marketCap":3381360},{"date":"2024-12-20","current":-0.214348,"twenty":-9.365914,"median":-1.339272,"eighty":-0.42489,"marketCap":3381360},{"date":"2024-12-27","current":-0.223982,"twenty":-9.343691,"median":-1.028151,"eighty":-0.42257,"marketCap":3533331},{"date":"2025-01-03","current":-0.235221,"twenty":-9.310356,"median":-1.010569,"eighty":-0.421624,"marketCap":3710631},{"date":"2025-01-10","current":-0.224785,"twenty":-9.310356,"median":-0.986085,"eighty":-0.419171,"marketCap":3545995},{"date":"2025-01-17","current":-0.196687,"twenty":-9.310356,"median":-0.982799,"eighty":-0.415922,"marketCap":3102746},{"date":"2025-01-24","current":-0.199898,"twenty":-9.293386,"median":-0.974419,"eighty":-0.403234,"marketCap":3153403},{"date":"2025-01-31","current":-0.18063,"twenty":-9.289144,"median":-0.972201,"eighty":-0.402144,"marketCap":2849460},{"date":"2025-02-07","current":-0.1718,"twenty":-9.289144,"median":-0.961273,"eighty":-0.392063,"marketCap":2710153},{"date":"2025-02-14","current":-0.117209,"twenty":-9.289144,"median":-0.955593,"eighty":-0.387742,"marketCap":1848983},{"date":"2025-02-21","current":-0.108378,"twenty":-9.27737,"median":-0.940824,"eighty":-0.3827,"marketCap":1709676},{"date":"2025-02-28","current":-0.097942,"twenty":-9.24551,"median":-0.936135,"eighty":-0.373943,"marketCap":1545040},{"date":"2025-03-07","current":-0.097139,"twenty":-9.219226,"median":-0.930908,"eighty":-0.369851,"marketCap":1532376},{"date":"2025-03-14","current":-0.083491,"twenty":-9.212374,"median":-0.928755,"eighty":-0.36451,"marketCap":1317084},{"date":"2025-03-21","current":-0.094731,"twenty":-9.173159,"median":-0.922298,"eighty":-0.358765,"marketCap":1494383},{"date":"2025-03-28","current":-0.256818,"twenty":-9.140169,"median":-0.914919,"eighty":-0.347994,"marketCap":3570947},{"date":"2025-04-04","current":-0.24709,"twenty":-9.135604,"median":-0.83876,"eighty":-0.336713,"marketCap":3435684},{"date":"2025-04-11","current":-0.311294,"twenty":-9.135604,"median":-0.828668,"eighty":-0.333105,"marketCap":4328420},{"date":"2025-04-17","current":-0.266546,"twenty":-9.074188,"median":-0.824365,"eighty":-0.330695,"marketCap":3706210},{"date":"2025-04-25","current":-0.334642,"twenty":-8.982065,"median":-0.805313,"eighty":-0.326015,"marketCap":4653052},{"date":"2025-05-02","current":-0.29573,"twenty":-8.951357,"median":-0.80139,"eighty":-0.323462,"marketCap":4111999},{"date":"2025-05-09","current":-0.417852,"twenty":-8.874587,"median":-0.792023,"eighty":-0.321722,"marketCap":5810061},{"date":"2025-05-16","current":-0.374587,"twenty":-8.797817,"median":-0.788244,"eighty":-0.322912,"marketCap":5208477},{"date":"2025-05-23","current":-0.41854,"twenty":-8.730186,"median":-0.783386,"eighty":-0.323462,"marketCap":5695070},{"date":"2025-05-30","current":-0.418096,"twenty":-8.693264,"median":-0.780083,"eighty":-0.324385,"marketCap":5689018},{"date":"2025-06-06","current":-0.481396,"twenty":-8.674986,"median":-0.774113,"eighty":-0.325566,"marketCap":6550347},{"date":"2025-06-13","current":-0.453606,"twenty":-8.659632,"median":-0.773127,"eighty":-0.327649,"marketCap":6172214},{"date":"2025-06-20","current":-0.423738,"twenty":-8.598216,"median":-0.764993,"eighty":-0.328805,"marketCap":5765794},{"date":"2025-06-27","current":-0.401528,"twenty":-8.575328,"median":-0.764089,"eighty":-0.329282,"marketCap":5463585},{"date":"2025-07-03","current":-0.400543,"twenty":-8.509992,"median":-0.761131,"eighty":-0.3298,"marketCap":5450187},{"date":"2025-07-11","current":-0.377896,"twenty":-8.393057,"median":-0.753737,"eighty":-0.331461,"marketCap":5142022},{"date":"2025-07-18","current":-0.378005,"twenty":-8.306491,"median":-0.749882,"eighty":-0.331844,"marketCap":5143511},{"date":"2025-07-25","current":-0.402786,"twenty":-8.291137,"median":-0.738662,"eighty":-0.332425,"marketCap":5480705},{"date":"2025-08-01","current":-0.396659,"twenty":-8.229721,"median":-0.709863,"eighty":-0.333284,"marketCap":5397337},{"date":"2025-08-08","current":-0.382929,"twenty":-8.196357,"median":-0.688579,"eighty":-0.334218,"marketCap":5210503},{"date":"2025-08-15","current":-0.384406,"twenty":-8.171954,"median":-0.668332,"eighty":-0.334595,"marketCap":5230601},{"date":"2025-08-21","current":-0.390076,"twenty":-8.116369,"median":-0.657281,"eighty":-0.335654,"marketCap":5249210}],"updateTime":1755888947155},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KTTA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555083875","title":"BRIEF-Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2555083875","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555083875?lang=en_us&edition=fundamental","pubTime":"2025-07-31 20:22","pubTimestamp":1753964560,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 TrialJuly 31 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS COMPLETES ENROLLMENT AND INITIAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUAB1LDSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2555884596","title":"Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort From Its Phase 1/1B Clinical Trial of Pas-004 in Adult Nf1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2555884596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555884596?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:01","pubTimestamp":1753959660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUAB1LDSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTAW","KTTA"],"gpt_icon":0},{"id":"2555880095","title":"Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2555880095","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555880095?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:01","pubTimestamp":1753959660,"startTime":"0","endTime":"0","summary":"– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July  31, 2025  (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124857/0/en/Pasithea-Therapeutics-Completes-Enrollment-and-Initial-Dosing-of-First-Cohort-from-its-Phase-1-1b-Clinical-Trial-of-PAS-004-in-Adult-NF1-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MTD","BK4007","BK4533","BK4181","BK4023","LU1093756325.SGD","LU0347712357.USD","LU1169590202.USD","PD","BK4548","LU2211817866.USD","PK","IE00BYQQ9H92.USD","KTTA","LU2413666426.HKD","BK4539","LU2413666699.HKD","IE00BFXG0V08.USD","BK4588","BK4218","LU1093756168.USD","LU1721428933.USD","LU1169589451.USD","BK4121","BK4567","BK4139","BK4585"],"gpt_icon":0},{"id":"2550896174","title":"Pasithea Sets Deadline for Shareholder Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2550896174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550896174?lang=en_us&edition=fundamental","pubTime":"2025-07-12 04:53","pubTimestamp":1752267229,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp ( ($KTTA) ) has issued an announcement. Pasithea Therapeutics Corp. has announced the date for its 2025 annual meeting o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pasithea-sets-deadline-for-shareholder-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pasithea-sets-deadline-for-shareholder-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2546729499","title":"Pasithea Therapeutics Receives Nasdaq Notice for Non-Compliance with $1 Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2546729499","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546729499?lang=en_us&edition=fundamental","pubTime":"2025-06-28 04:06","pubTimestamp":1751054770,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation has announced that it received a notice from the Nasdaq Stock Market on June 23, 2025, indicating non-compliance with the $1.00 minimum bid price requirement necessary for continued listing on the Nasdaq Capital Market. This notice does not lead to immediate delisting of the company's common stock. Pasithea has 180 calendar days, until December 22, 2025, to regain compliance by ensuring its stock closes at or above $1.00 per share for at least ten consecutive business days. The company is exploring options, including a potential reverse stock split, to address the issue. If compliance is not regained within this period, an additional 180-day period may be available, provided other listing criteria are met. Failure to comply could result in delisting, subject to appeal. This development does not affect the company's operations or SEC reporting requirements.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL3NxxYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2545170768","title":"Pasithea Therapeutics Increases Offering Price to $4.23M, Registers Additional $2.15M in Common Stock Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170768","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170768?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:21","pubTimestamp":1750450861,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation has increased the maximum aggregate offering price of its common stock under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC, from $2,076,000 to $4,227,000. As of June 20, 2025, the company registered an additional $2,151,000 worth of shares to be sold. Prior to this, Pasithea sold shares totaling approximately $2,075,688 under the agreement. The specific number of shares and price per share are not detailed in the document.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL69XbRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Pasithea Therapeutics Increases Offering Price to $4.23M, Registers Additional $2.15M in Common Stock Sales","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA"],"gpt_icon":0},{"id":"2540798208","title":"Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798208","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798208?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:36","pubTimestamp":1748867764,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced updated interim results from its ongoing dose escalation Phase 1 study evaluating PAS-004 in advanced cancer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-presents-updated-interim-data-from-phase-1-pas-004-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-presents-updated-interim-data-from-phase-1-pas-004-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","KTTA","BK4539","BK4007"],"gpt_icon":0},{"id":"2535683498","title":"Tiago Marques, CEO of Pasithea Therapeutics, Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2535683498","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535683498?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:55","pubTimestamp":1747274155,"startTime":"0","endTime":"0","summary":"Tiago Marques, Chief Executive Officer and Director of Pasithea Therapeutics Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL1m91bN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2535812026","title":"BRIEF-Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2535812026","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535812026?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:06","pubTimestamp":1747224394,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial SiteMay 14 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA9DFBJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTAW","KTTA"],"gpt_icon":0},{"id":"2533255962","title":"Press Release: Pasithea Therapeutics Announces Closing of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533255962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533255962?lang=en_us&edition=fundamental","pubTime":"2025-05-08 05:00","pubTimestamp":1746651600,"startTime":"0","endTime":"0","summary":"Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public Offering. The Series C warrants have an exercise price of $1.40 per share, are exercisable upon issuance and will expire five years thereafter. The Series D warrants have an exercise price of $1.40 per share, are exercisable upon issuance and will expire 18 months thereafter. Simultaneously with the closing of the offering, certain investors exercised Series D warrants to purchase an aggregate of 914,286 shares of common stock, resulting in additional gross proceeds to the Company of approximately $1.3 million.The securities described above were offered pursuant to a registration statement on Form S-1  originally filed with the Securities and Exchange Commission  on May 1, 2025 and declared effective on May 6, 2025. The offering was made only by means of a prospectus, which is part of the effective registration statement. A final prospectus relating to the offering ha","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4139","BK4007","PK","BK4023","BK4181","LENZ","KTTA","BK4135","PD","CNS","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2533433654","title":"BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533433654","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533433654?lang=en_us&edition=fundamental","pubTime":"2025-05-07 00:18","pubTimestamp":1746548292,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Announces Pricing Of $5 Million Public OfferingMay 6 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERINGSource text: ID:nGNX58PWjJFurther company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE2EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2533065947","title":"Pasithea Therapeutics Prices $5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2533065947","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533065947?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:38","pubTimestamp":1746545880,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Tuesday it priced a $5 million public offering consisting of nearly 3.6 million common shares, or pre-funded warrants, at $1.40 per share.The offering includes series C warrants, which expire in five years, and series D warrants, which expire in 18 months, both exercisable at $1.40 per share.The offering is expected to close around Wednesday, pending the fulfillment of customary closing conditions.The company plans to use the proceeds for general corporate purposes such as research, clinical trials, technology development, potential acquisitions, and working capital, the company said.Shares of the biotechnology company rose more than 35% in recent Tuesday trading.Price: 1.92, Change: +0.50, Percent Change: +35.21","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KTTA","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2533659448","title":"Pasithea Therapeutics 3.57M share Secondary priced at $1.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2533659448","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533659448?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:35","pubTimestamp":1746545733,"startTime":"0","endTime":"0","summary":"The gross proceeds to the company from the offering are expected to be approximately $5M, before deducting the placement agent’s fees and other off...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-3-57m-share-secondary-priced-at-1-40?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-3-57m-share-secondary-priced-at-1-40?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","KTTA"],"gpt_icon":0},{"id":"2532591798","title":"Pasithea Therapeutics Corporation Unveils Presentation on Development and Commercialization Plans for PAS-004 in Advanced Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532591798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532591798?lang=en_us&edition=fundamental","pubTime":"2025-05-02 09:48","pubTimestamp":1746150515,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation Unveils Presentation on Development and Commercialization Plans for PAS-004 in Advanced Cancer Treatment. Pasithea Therapeutics Corporation has released an investor presentation detailing its current corporate overview and ongoing projects. The presentation provides insights into the company's pipeline developments, including the clinical trial progress of its product candidate, PAS-004, for advanced cancer patients. It highlights the company's focus on advancing its clinical and preclinical candidates and discusses the design and conduct of its ongoing Phase 1 clinical trial. The presentation also addresses the company's plans for future operations, including the pursuit of new indications and the filing of regulatory documents. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL4Zty9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2532000524","title":"BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000524","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000524?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:21","pubTimestamp":1746116464,"startTime":"0","endTime":"0","summary":"BRIEF-Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC FilingMay 1  - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS FILES FOR OFFERING UP TO 3.2 MILLION COMMON SHARES TOGETHER WITH WARRANTS - SEC FILINGSource text: [ID:n0001213900-25-038088]Further company coverage: KTTA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nFWN3R92EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2531789494","title":"Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789494?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:18","pubTimestamp":1745925516,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-completes-enrollment-in-cohort-6-of-phase-1-trial-of-pas-004?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-completes-enrollment-in-cohort-6-of-phase-1-trial-of-pas-004?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2531314781","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531314781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531314781?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":"MIAMI, April 29, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics , pharmacodynamics , and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-completion-enrollment-110200697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4007","AEIS","BK4157","LENZ","LU1169590202.USD","BK4023","PK","BK4181","BK4218","KTTA","LU1169589451.USD","PD","KTTAW","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4139","IE0031619046.USD","IE00B7SZL793.SGD","CNS"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGNPF","BK4139","MIRA","NRXP","GHRS","SILO","BK4539","ALID","IXHL","SNPX","BK4007","KTTA","MDXXF","BK4202","CMPS","BK4547","BETRF","NUMIF","ATAI","PBM","DRUG","CMND","CYBN","ENVB","SEEL","FLHLF","RLMD","PHRRF","BK4168","ENTBF","QNTM","MNMD","MYCOF","SPRC","OPTHF","PSYGF","RVVTF"],"gpt_icon":0},{"id":"2529607368","title":"Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529607368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529607368?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:02","pubTimestamp":1745492520,"startTime":"0","endTime":"0","summary":"Poster presentation on Monday, June 2, 2025 from 1:30 – 4:30 PM CDT at the ASCO Annual Meeting. MIAMI, April 24, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology  taking place May 30 – June 3, 2025, in Chicago, Illinois.The Company will present updated interim clinical data from its onging Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-present-updated-data-110200343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","LENZ","IE00B66KJ199.SGD","KTTAW","KTTA","CNS","BK4023","IE0031619046.USD","BK4007","AEIS","PK","PD","LU1169590202.USD","BK4157","LU1169589451.USD","BK4135","IE00B19Z4B17.USD","BK4218","BK4181","BK4139"],"gpt_icon":0},{"id":"2526659586","title":"Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526659586","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526659586?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:13","pubTimestamp":1744294382,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Thursday that the external Safety Review Committee recommended that the company's phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, in advanced cancer should proceed to cohort 6, 30mg capsules, without any modification.The recommendation was based on the review of the safety data from three patients from cohort 5 and the absence of any dose limiting toxicities, or DLT, the biotechnology company said.During the DLT period, no rash was observed to date in any of the first 19 patients in either capsule or tablet formulation of PAS-004. Rash is a common adverse event that is observed at low doses with competitor MEK inhibitors, Pasithea said.Shares were up 50% in early Thursday trading.Price: 1.62, Change: +0.54, Percent Change: +50.00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","IE00B19Z4B17.USD","AEIS","IE0031619046.USD","BK6522","IE00B7SZL793.SGD","BK4007","KTTA","BK4157","IE00B66KJ199.SGD","BK6088","BLZ.SI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}